These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30075497)

  • 1. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
    Einama T; Kamachi H; Tsuruga Y; Sakata T; Shibuya K; Sakamoto Y; Shimada S; Wakayama K; Orimo T; Yokoo H; Kamiyama T; Katoh N; Uchinami Y; Mitsuhashi T; Taketomi A
    Medicine (Baltimore); 2018 Aug; 97(31):e11309. PubMed ID: 30075497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anterior approach to the superior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma.
    Mizuno S; Isaji S; Tanemura A; Kishiwada M; Murata Y; Azumi Y; Kuriyama N; Usui M; Sakurai H; Tabata M
    J Gastrointest Surg; 2014 Jun; 18(6):1209-15. PubMed ID: 24664421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
    Kubota K; Sato T; Watanabe S; Hosono K; Kobayashi N; Mori R; Taniguchi K; Matsuyama R; Endo I; Nakajima A
    Dig Endosc; 2014 Jan; 26(1):77-86. PubMed ID: 23551230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
    Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy.
    Kamachi H; Tsuruga Y; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamiyama T; Katoh N; Taketomi A
    In Vivo; 2018; 32(5):1183-1191. PubMed ID: 30150442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detailed analysis of extra-pancreatic nerve plexus invasion in pancreatic body carcinoma analyzed by 50 consecutive series of distal pancreatectomy with en-bloc celiac axis resection.
    Tsuchikawa T; Hirano S; Nakamura T; Okamura K; Tamoto E; Murakami S; Kurashima Y; Ebihara Y; Shichinohe T
    Hepatogastroenterology; 2015; 62(138):455-8. PubMed ID: 25916081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
    Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
    Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
    Takahashi H; Akita H; Tomokuni A; Kobayashi S; Ohigashi H; Fijiwara Y; Yano M; Sakon M; Ishikawa O
    Ann Surg; 2016 Dec; 264(6):1091-1097. PubMed ID: 27462960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
    J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
    Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
    Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
    Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
    J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.
    Kim MS; Lim JS; Hyung WJ; Lee YC; Rha SY; Keum KC; Koom WS
    World J Gastroenterol; 2015 Mar; 21(9):2711-8. PubMed ID: 25759540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
    Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB
    J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.
    Fujii T; Yamada S; Murotani K; Kanda M; Sugimoto H; Nakao A; Kodera Y
    Medicine (Baltimore); 2015 Sep; 94(39):e1647. PubMed ID: 26426657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
    Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
    Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
    Sho M; Akahori T; Tanaka T; Kinoshita S; Tamamoto T; Nomi T; Yamato I; Hokuto D; Yasuda S; Kawaguchi C; Nishiofuku H; Marugami N; Enomonoto Y; Kasai T; Hasegawa M; Kichikawa K; Nakajima Y
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):197-205. PubMed ID: 22766692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.